celecoxib has been researched along with okadaic acid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aggarwal, BB; Koul, D; Shishodia, S | 1 |
1 other study(ies) available for celecoxib and okadaic acid
Article | Year |
---|---|
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Topics: Carcinogens; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclin D1; Cyclooxygenase Inhibitors; Enzyme Activation; Genes, Reporter; Humans; I-kappa B Kinase; I-kappa B Proteins; Interleukin-1; Lipopolysaccharides; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase Inhibitors; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Okadaic Acid; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Tetradecanoylphorbol Acetate; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |